SWITCH FROM INTRAVENOUS TO SUB-CUTANEOUS INFLIXIMAB IN INFLAMMATORY BOWEL DISEASE: WHICH CONSEQUENCES FROM A PHARMACOKINETIC PERSPECTIVE?

Camille Tron  1     Bénédicte Franck  1     Marie-Clémence Verdier  1     Florian Lemaitre  1     Guillaume Bouguen  2    
1 Rennes University Hospital, Rennes, France
2 CHU Pontchaillou, Rennes, France

Session
IBD (Posters)

Conference
UEG Week 2022

Citation
United European Gastroenterology Journal 2022; 10 (Supplement 8)

Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Social Sharing